U.S. markets open in 4 hours 5 minutes

  • S&P Futures

    3,905.00
    -3.00 (-0.08%)
     

  • Dow Futures

    31,238.00
    -30.00 (-0.10%)
     

  • Nasdaq Futures

    13,673.00
    -10.00 (-0.07%)
     

  • Russell 2000 Futures

    2,282.00
    -3.80 (-0.17%)
     

  • Crude Oil

    58.15
    +0.18 (+0.31%)
     

  • Gold

    1,847.30
    +13.10 (+0.71%)
     

  • Silver

    27.84
    +0.27 (+0.98%)
     

  • EUR/USD

    1.2107
    +0.0050 (+0.41%)
     

  • 10-Yr Bond

    1.1600
    0.0000 (0.00%)
     

  • Vix

    21.84
    +0.97 (+4.65%)
     

  • GBP/USD

    1.3766
    +0.0028 (+0.21%)
     

  • USD/JPY

    104.6410
    -0.5770 (-0.55%)
     

  • BTC-USD

    46,223.58
    +7,017.96 (+17.90%)
     

  • CMC Crypto 200

    926.72
    -5.16 (-0.55%)
     

  • FTSE 100

    6,519.22
    -4.31 (-0.07%)
     

  • Nikkei 225

    29,505.93
    +117.43 (+0.40%)
     

Electronic Skin Market Size To Witness Expansion At 20.5% CAGR By 2027, Owing To Rising Technological Development in Healthcare Sector | Million Insights

·5 min read

FELTON, Calif., Feb 9, 2021 /PRNewswire/ -- The global electronic skin market size is estimated to touch USD 19.6 billion, by the end of 2027, and is anticipated to grow at a CAGR of 20.5% over the forecast period, 2020 to 2027, according to a new report by Million Insights. The increasing aging population along technological development in healthcare is mainly boosting market growth. Additionally, in the e-textile field, researchers use 3D printing for harvest & storing electricity. In addition, the companies have increased their expenditure on R&D development, which is projected to foster market growth.

Grand View Research, Inc. (PRNewsfoto/Grand View Research, Inc.)
Grand View Research, Inc. (PRNewsfoto/Grand View Research, Inc.)

For example, Xenoma has developed an e-skin that can monitor health & fitness using printed circuit fabric. Several researchers in the medical are focusing on e-skin application using biomedical and robotic systems. The soft sensors are placed on the skin and the data collected is then integrated with the machine learning process for monitoring tract treatment. In addition, the sensors also track biological parameters like motion, cardiac rhythm, temperature, and breathing.

Please click here to get the sample pdf and find more details on "Electronic Skin Market" Report 2027.

Several players in the industry offer soft biosensor systems that help to measure medical data continuously. The e-skins are effective than normal check-ups, that can monitor electric pulse easily. The growing emphasis on self-monitoring and rising diabetes patients are also contributing to market growth. According to the International Diabetes Federation, the total diabetic patient number is projected to increase by up to 700 million by 2045.

Further key findings from the report suggest:

  • In 2019, North America held the largest market share in the global market.

  • Based on product, the electronic patches segment is projected to dominate the market over the forecast period.

  • The stretchable circuit component segment led the market on owing to its rising application in e-textile and healthcare sectors.

  • By Sensors, the tactile sensor segment is anticipated to expand at the highest CAGR from 2020 to 2027.

  • The drug delivery system application segment is projected to grow the fastest growing CAGR over the forecast period.

  • Key players in the industry continuously focus on developing innovative products by investing in R&D activities.

Browse 108 page research report with TOC on "Global Electronic Skin Market" at: https://www.millioninsights.com/industry-reports/global-electronic-skin-market

Million Insights has segmented the global electronic skin market on the basis of product, component, sensor, application, and region:

  • Electronic Skin Product Outlook (Revenue, USD Billion, 2016 - 2027)

  • Electronic Skin Component Outlook (Revenue, USD Billion, 2016 - 2027)

  • Electronic Skin Sensors Outlook (Revenue, USD Billion, 2016 - 2027)

  • Electronic Skin Application Outlook (Revenue, USD Billion, 2016 - 2027)

  • Electronic Skin Regional Outlook (Revenue, USD Billion, 2016 - 2027)

  • North America

  • Europe

  • Asia Pacific

  • Latin America

  • Middle East & Africa

  • List of Key Players in Electronic Skin Market

Explore the Latest Press Releases by Million Insights:

  • Automotive Cyber Security Market - The global automotive cyber security market is projected to reach USD 5.56 billion by 2025. A growing data breaching incidence owing to increasing number of automated and connected vehicles is a major factor driving the market growth.

  • Electric Vehicle Market - The demand for the global electric vehicle market is projected to value at $1,212.1 billion by 2027, with a CAGR of 41.5 % from 2020 to 2027. The growth can be imputed to the number of government initiatives across the globe to promote the adoption and manufacturing of EVs.

  • Kids Bicycle Market - The global kids bicycle market size is expected to register revenue of USD 4.9 billion by the end of 2025. It is expected to grow with a 2.6% CAGR from 2019 to 2025. This growth can be attributed to increasing demand for bicycles with attractive colors and features among kids coupled with rising awareness about health benefits associated with bicycle riding.

  • Baseball Equipment Market - The global baseball equipment market size is projected to touch USD 19.2 billion by the end of 2025. It is estimated to grow with a CAGR of 3.3% from 2019 to 2025. Baseball is earning widespread popularity, especially among youngsters and adults due to extensive media coverage and the introduction of several leagues and tournaments of baseball across the globe.

About Million Insights:

Million Insights, is a distributor of market research reports, published by premium publishers only. We have a comprehensive marketplace, that will enable you to compare data points, before you make a purchase. Enabling informed buying, is our motto and we strive hard to ensure that our clients get to browse through multiple samples, prior to an investment. Service flexibility & the fastest response time are two pillars, on which our business model is founded. Our market research report store includes in-depth reports, from across various industry verticals, such as healthcare, technology, chemicals, food & beverages, consumer goods, material science & automotive.

Contact:
Ryan Manuel
Research Support Specialist, USA
Million Insights
Phone: 1-408-610-2300
Toll Free: 1-866-831-4085
Email: sales@millioninsights.com
Web: https://www.millioninsights.com/
Follow Us: LinkedIn | Twitter

Cision
Cision

View original content:http://www.prnewswire.com/news-releases/electronic-skin-market-size-to-witness-expansion-at-20-5-cagr-by-2027--owing-to-rising-technological-development-in-healthcare-sector--million-insights-301224290.html

SOURCE Million Insights

Latest Stories

  • 3 Monster Growth Stocks That Are Still Undervalued

    Let’s talk about growth. With corona receding, politics growing less exciting, and a new year ahead, investors are getting optimistic – and that means there’s a hunt for stocks that will bring in strong returns. In other words, growth stocks. In a recent interview, Jan Hatzius, chief economist at investment giant Goldman Sachs, said that he sees GDP growth in 2Q21 hitting as high as 10%. In an environment like that, most stocks are going to show a growth trend. Now, we all know that past performance won’t guarantee future results. Still, the best place to start looking for tomorrow’s high-growth stocks is among yesterday’s winners. Bearing this in mind, we set out to find stocks flagged as exciting growth plays by Wall Street. Using TipRanks’ database, we locked in on three analyst-backed names that have already notched impressive gains and boast solid growth narratives for the long-term. Kaleyra (KLR) We will start with Kaleyra, a cloud computing company offering communications solutions. The company’s SaaS platform supports SMS, voice calls, and chatbots – a product with obvious applications and value in today’s office climate, with the strong push to telecommuting and remote work. Kaleyra boasts over 3,500 customers, who make 3 billion voice calls and sent 27 billion text messages in 2019 (the last year with full numbers available). Over the past 6 months, KLR shares have shown tremendous growth, appreciating 155%. Kaleyra’s revenues have grown along with the share value. The company’s 3Q20 results hit $38.3 million, the best since KLR went public. While Kaleyra still runs a net earnings loss each quarter, the Q3 EPS was the lowest such loss in the past four quarters. Maxim analyst Allen Klee is bullish on KLR, seeing recent growth and product offerings as indicative of future performance. “Over the past few years, Kaleyra has posted double-digit revenue growth and positive adjusted EBITDA. We forecast revenue growth of 9%, 22%, and 28% for 2020-2022. We project adjusted EBITDA declines in 2020 to reflect public company costs and COVID-19, but growth at over twice the rate of revenue for the following two years. We expect benefits from operating leverage, low-cost tech employees, cost volume discounts as the company expands, and margin improvement from new offerings and geographies. Over the longer term, we believe the company can grow revenue close to 30% with even faster bottom line growth," Klee opined. With such growth, it’s no wonder Klee takes a bullish stance on KLR. To kick off his coverage, the analyst published a Buy rating and set a $22 price target. This figure implies a 45% for the coming year. (To watch Klee’s track record, click here) Overall, based on the 3 Buy ratings vs no Holds or Sells assigned in the last three months, Wall Street analysts agree that this ‘Strong Buy’ is a solid bet. It also doesn’t hurt that its $19 average price target implies ~26% upside potential. (See KLR stock analysis on TipRanks) Vista Outdoor (VSTO) Next up, Vista Outdoor, is a venerable company that saw its niche gain attractiveness in recent times. Vista is a sporting goods company, with 40 brands in two main divisions: outdoor products and shooting sports. Vista’s brands include well-known names as Bushnell Golf, CamelBak, and Remington. The company has found a burst of success in the ‘corona year’ as people have turned more and more to outdoor activities that can be practiced solo or in small groups – expanding the customer base. VSTO shares are up as a result, by 214% in the last 12 months. Vista’s earnings reflect the increase in consumer interest in outdoor sports. The company’s EPS grew in 2020, turning from a net loss to a $1.34 per share profit in the fiscal Q2 report (released in November). The fiscal Q3 report, released earlier this month, showed lower earnings, at $1.31 per share, but was still considered solid by the company, as it covered winter months when the company normally sees a revenue decline. Both quarters showed strong year-over-year EPS gains. Covering Vista for B. Riley, 5-star analyst Eric Wold sees several avenues for continued growth by Vista. He is impressed by the growth in firearm and ammunition sales, and by the price increase for products in both the outdoor goods and the shooting sports divisions. “Given our expectation that the increased industry participation numbers for both outdoor products and shooting sports during the pandemic will represent an incremental tailwind for VSTO in the coming years beyond the impressive production visibility that has been created by depleted channel inventory levels, we continue to see an attractive set-up for baseline growth,” Wold commented. Overall, Wold is bullish on the stock and rates it a Buy, with a $41 price target. This figure indicates room for 27% upside in the coming year. (To watch Wold’s track record, click here) Vista is another company with a unanimous Strong Buy consensus rating. That rating is based on 9 recent reviews, all to Buy. VSTO shares have an average price target of $36.78, which gives an upside of 14% from the trading price of $32.15. (See VSTO stock analysis on TipRanks) Textainer Group Holdings (TGH) You might not think about the ubiquitous cargo container, but these deceptively simple metal boxes have changed the face of bulk transport since their breakout proliferation in the 1960s. These containers make it easy to organize, load, ship, and track vast amounts of cargo, and are especially valuable for their ease of switching; containers can be quickly loaded on or switched between ships, trains, and trucks. Textainer is a billion-dollar company that buys, owns, and leases shipping containers for the cargo industry. The company has over 250 customers, and boasts a fleet of 3 million twenty-foot equivalent units (TEUs). Textainer is also a major reseller of used containers, and operates from 500 depots around the world. Even during the corona pandemic, when international trading routes and patterns were badly disrupted, and the quarterly revenues were down year-over-year, Textainer saw share gains. The company’s stock soared 110% over the past 12 months. The bulk of these gains have come in the past six months, as economies – and trading patterns – have begun to reopen. Looking at Textainer for B. Riley, analyst Daniel Day is deeply impressed. He sees this company as the lowest priced among its peer group, with a strong market share in a competitive industry. Day rates TGH a Buy, and his $31 price target suggests it has room for 57% growth ahead of it. In support of this bullish stance, Day writes, in part, “We believe that TGH is an underfollowed, misunderstood name that is ideal for the portfolio of a deep value investor looking for cash flow–generative names trading at a steep discount to intrinsic value. With new container prices at multiyear highs amid a resurgence in container shipping, we expect upcoming earnings results to be positive catalyst events for TGH…” Some stocks fly under the radar, and TGH is one of those. Day's is the only recent analyst review of this company, and it is decidedly positive. (See TGH stock analysis on TipRanks) To find good ideas for growth stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights. Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.

  • Only one US stock has done better than Amazon in the Jeff Bezos era

    With Jeff Bezos stepping down as CEO of Amazon.com, let’s reflect on the company’s performance under his management. A $1,000 investment in Amazon’s stock at its IPO on May 15, 1997, would be worth $2.2 million today. A $1,000 investment in Hansen’s Natural Corp—what Monster was called in 1997—would be worth $3.9 million.

  • Is Nio Stock A Buy As Electric Vehicle Sales Surge In New Year?

    Nio is growing its lineup of electric vehicles as sales boom for the emerging Tesla of China. But is Nio stock a buy right now?

  • Best Tech Stocks To Buy Or Watch Now: 5 Growth Stocks Leading The Stock Market

    The best tech stocks to buy and watch are strong price performers with healthy fundamentals, thanks to a new product or service that's driving growth.

  • Should GE Try To Acquire FuelCell Or Plug Power In 2021?

    Every week, Benzinga conducts a survey to collect sentiment on what traders are most excited about, interested in or thinking about as they manage and build their personal portfolios. This week we posed the following question to over 1,000 traders and investors on whether General Electric Company (NYSE: GE) should acquire a clean energy manufacturing company: Over the next year, should GE buy FuelCell or Plug Power? Buy FuelCell Energy Inc (NASDAQ: FCEL)? Buy Plug Power Inc (NASDAQ: PLUG)? Buy Neither? About GE General Electric is known for its digital industrial offerings and massive installed base spread across a variety of products and services, including aircraft engines, gas turbines, wind turbines, and medical diagnostic equipment, among others. After the sale of GE Transportation to Wabtec and a majority of its stake in Baker Hughes, as well as the sale of GE Biopharma to Danaher, the company's focus turns to aviation, legacy healthcare, power and renewable energy. The Boston-based conglomerate’s market cap comes in at nearly $100 billion, more than double FuelCell ($7.7 billion) and Plug Power’s ($32.7 billion) market caps combined. See Also: How To Buy GE Stock Sentiment was extremely tight for this study. Our survey revealed 39% think GE should complete an M&A deal with FuelCell in 2021. FuelCell Energy designs manufactures, sells, installs, operates, and services fuel-cell products, which efficiently convert chemical energy in fuels into electricity through a series of chemical reactions. Meanwhile, 43% believe GE would be better served acquiring Plug Power by the end of the year. Plug Power provides hydrogen fuel cell turnkey solutions for the electric mobility and stationary power markets in North America and Europe. The clean energy company focuses on proton exchange membrane fuel cell and fuel processing technologies, fuel cell and battery hybrid technologies and related hydrogen storage and dispensing infrastructure. Plug Power garnered an abundance of attention from investors in 2020 for its GenDrive system, a hydrogen-fueled PEM fuel cell system that provides power to material handling electric vehicles. Only 18% thought GE should not acquire either clean energy manufacturing company in 2021. Buy FuelCell 39.40% Buy Plug Power 42.70% Buy Neither 17.90% This survey was conducted by Benzinga in February 2021 and included the responses of a diverse population of adults 18 or older. Opting into the survey was completely voluntary, with no incentives offered to potential respondents. The study reflects results from over 1,000 adults. See more from BenzingaClick here for options trades from BenzingaHere's Why Marathon Patent, Riot, Westport Fuel and Clean Energy Are MovingTesla's Rumored ,000 Model 2 For China Could Be Unveiled In Late 2021: Report© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • Bionano Stock Gets a New Street-High Price Target

    The last few months have been a breakout period for Bionano Genomics (BNGO). The share price has gone stratospheric as investors have cottoned on to the potential of its genome imaging system, Saphyr, and the impact Bionano can have in the world of cytogenetics. Oppenheimer analyst Kevin DeGeeter believes technical developments could lead to reduced COGs (cost of goods sold) per genome, which in turn could help the next-gen platform gain “deeper market penetration.” “Since the 2017 launch of Saphyr, there has been steady improvement in both laser optics and photon capture components from OEMs,” the 5-star analyst said. “BNGO is launching an aggressive initiative to combine these improved components with new informatics workflow to support a stepwise increase in throughput from 5,000 genomes per year to 68,000 (four modules @ 17,000) and chip cost from $500 to $100 per genome.” While cytogenetics remains the bull case’ main driver, the optical imaging platform’s addressable market could expand via newly planned studies in other verticals including prenatal, pediatrics, hematology and solid tumors. DeGeeter also believes the recent equity raises which totaled more than $380 million give the company “balance sheet flexibility.” Therefore, the analyst is more focused on the company’s progress than near-term revenue prospects. The strengthened balance sheet allows Bionano to “aggressively invest in both commercial infrastructure expansion and next-generation optical imaging technologies.” DeGeeter thinks that by 2026, 3 full years into the launch of a “next-generation platform offering up to 80% reduction in per genome disposable cost,” the company can deliver revenue of $353.1 million. Overall, the analyst estimates the cytogenetics TAM (total addressable market) could reach more than $1.5 billion. To this end, DeGeeter reiterates a Buy rating on Bionano shares and boosts the price target up from $1.5 all the way to a Street high of $15. Investors could be pocketing gains of 29%, should DeGeeter's thesis play out over the coming months. (To watch DeGeeter’s track record, click here) That’s Oppenheimer’s take, what about the rest of the Street’s view? 2 other analysts agree by providing additional Buy ratings, while one Hold can’t detract from a Strong Buy consensus rating. However, the $10.94 average price target is dragged down by the latter’s depressed objective, and therefore, shares are anticipated to remain range-bound for the foreseeable future. (See BNGO stock analysis on TipRanks) To find good ideas for healthcare stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights. Disclaimer: The opinions expressed in this article are solely those of the featured analyst. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.

  • Your next stimulus check is just weeks away — will you get the full $1,400?

    Congressional leaders are hurrying the new payments along. Will you get one — and when?

  • What Do The Pros Think About Tesla's Bitcoin Investment?

    Tesla Inc (NASDAQ: TSLA) investor Ron Baron says the company's decision to invest $1.5 billion in Bitcoin (BTC) and accept the digital currency as a payment option is "not surprising." Musk Likes Bitcoin: Tesla CEO Elon Musk has been "commenting favorably" on bitcoin for a while, Baron said in the statement to CNBC. It's likely Tesla is not "speculating on the price of bitcoin," rather using it as a payment system. Other heavyweight investors such as Stanley Druckenmiller and Paul Tudor Jones, CIO of Tudor Investment Corp., are equally bullish on bitcoin, while companies like Paypal Holdings Inc (NASDAQ: PYPL) are building out its digital currency offerings. "I'm sure a lot of thought went into bitcoin purchase by Tesla and I look forward to learning the rationale," according to Baron, the CEO, chairman and portfolio manager of Baron Funds. Related Link: 15 Bitcoin Stocks To Watch On Tesla News Loup Ventures' Gene Munster also likes the move. "Tesla has money to lose with $19 billion in assets," Munster told Benzinga. "Yes, Bitcoin can move the needle for Tesla. If it goes up 10x, that's $15 billion to Tesla. That's real money." Bitcoin Investment: Tesla's decision to allocate around 7.5% of its total cash into bitcoin and could be seen as a signal to customers it "understands where the world is going," Galaxy Digital CEO Michael Novogratz told CNBC. People want to do business and invest in companies that are looking forward to the next 100 years — not the last 100 years. On the other hand, Musk shouldn't be tweeting about Dogecoin as the digital currency's appreciation has reached a point where some people will lose a lot of money, he said. The digital coin has no real purpose, unlike bitcoin or Ethereum and others. "It was funny for a little bit," Novogratz said. Hard To Prove Any Manipulation: Musk has been bullish on bitcoin for some time and this begs the question if his public comments can be seen as market manipulation. Muddy Waters Research Founder Carson Block said he doesn't think this is the case. Musk is far from the only notable persona in the investment community to publicly comment on what he is bullish on. Musk's comments are no different from Chamath Palihapitiya confirming he is long GameStop Corp. (NYSE: GME) call options. Meanwhile, the U.S. Securities and Exchange Commission "does not have a record of success" against Musk, Block told CNBC. As such, any investigation would likely lead to a "dead end." See more from BenzingaClick here for options trades from BenzingaWhy This Stock Is A Derivative Play On The Rise Of ClubhouseEtsy Hits New All-Time Highs After Elon Musk Tweets His Approval© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • Is Tilray Set For Another Short Squeeze?

    Cannabis companies have seen their share prices rise significantly this year as U.S. lawmakers look set to tackle federal marijuana reform measures. What Happened: Shares of Tilray Inc. (NASDAQ: TLRY) have gained over 250% since the start of January. Traders and investors could be wondering if this is the beginning of a second big short squeeze for the cannabis cultivator. Why It Matters: In the three months after it went public in June 2018, Tilray share prices shot up over 1,400% reaching $300 per share in September of that year after short sellers were forced to cover their positions due to its tight float structure and lack of shares available for purchase. At the time, short interest on Tilray sat at about 33%. Although share prices of Tilray have risen sharply over the last five weeks, the short interest is sitting much higher at approximately 51%. This hasn’t gone unnoticed by the online trading communities, which have recently targeted Tilray in much the same way they drove up the share prices of companies such as GameStop Corporation (NYSE: GME) and AMC Entertainment Holdings Inc. (NYSE: AMC) — two other stocks with high levels of short interest. The Week In Cannabis: Stocks Up On Jazz Pharma's GWPH Acquisition, Potential Federal Moves What’s Next: After peaking in 2018, shares of Tilray quickly fell after investors glimpsed into the company’s fundamentals and were unable to justify its value. Its situation has changed over the last year, however, and investors have regained interest in the company. In the last few months, Tilray has made major announcements, including its plans to merge with Aphria (NASDAQ: APHA) to become the largest cannabis producer in the world. Although retail investors can take the credit for Tilray’s last big squeeze, the next one could be brought on by institutional investors who might hop on board if banks gain the ability to access cannabis companies through the passage of the MORE Act. TLRY Price Action: The stock closed Monday's session up 16.9% at $30.09. Photo courtesy of Tilray. See more from BenzingaClick here for options trades from BenzingaHere's Why Estée Lauder Is Impressing AnalystsTesla Receives Significant Warning From Chinese Regulator© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • 7 public companies with exposure to bitcoin

    Now that Tesla has invested significantly in bitcoin, Fundstrat's Tom Lee points to seven companies as ways to invest in the digital currency.

  • EV Company With Almost No Revenue Posts 3,000% Gain in 8 Months

    (Bloomberg) -- There is nothing about the finances of Blink Charging Co. that would suggest it’s one of the hottest stocks in America.It’s never posted an annual profit in its 11-year history; it warned last year it could go bankrupt; it’s losing market share, pulls in anemic revenue and has churned through management in recent years.And yet a hot stock it is. Investors have bid Blink’s share price up 3,000% over the past eight months. Only seven stocks -- out of about 2,700 that are worth at least $1 billion -- have risen more over that time. The reason: Blink is a green-energy company, an owner and operator of charging stations that power up electric vehicles. And if investors are certain of one thing in the mania that is sweeping through financial markets, it is that green companies are can’t-miss, must-own investments of the future.No stock better captures this euphoria than Blink. With a market capitalization of $2.17 billion as of Monday, its enterprise value-to-sales ratio -- a common metric to gauge whether a stock is overvalued -- has blown out to 481. For some context, at Tesla Inc. -- the darling of the EV world and a company with a very rich valuation itself -- that number is just 26.“Everything about it is wrong,” said Andrew Left, the founder of Citron Research. “It is just a cute name which caught the eye of retail investors.”Citron was one of a handful of firms that bet against Blink last year, putting on short-sale trades that would pay off if the share price fell. It’s one of several wagers against stocks favored by the retail-investment crowd that have gone against Citron -- with GameStop Corp. being the most high-profile -- and prompted Left to declare Jan. 29 that the firm was abandoning its research into short-selling targets. Overall short interest on Blink -- a gauge of the amount of wagers against the stock -- has fallen to under 25% of free-floating shares from more than 40% in late December.For the short-sellers, one of the things that raised alarms is that several figures tied to Blink, including CEO and Chairman Michael Farkas, were linked to companies that ran afoul of securities regulations years ago.Farkas dismisses this and the other criticisms lobbied by the shorts. “There have been and always will be naysayers,” Farkas said in an email. “When I founded the business, the naysayers questioned whether the shift to EV was real. Now, as the value of our business grows, the naysayers tend to be the short sellers.”Also See: Bloomberg Intelligence’s Environmental, Social, and Corporate Governance DashboardIn the CrosshairsMaking money on charging is, historically, a losing proposition. In theory, a model like Blink’s that involves both equipment sales and collecting user fees could become consistently profitable as government support accelerates EV adoption. But no one’s done it yet.“This market is still too small and early-stage,” said Pavel Molchanov, an analyst at Raymond James & Associates. “It will take time for economies of scale to materialize.”Even by the industry’s fairly forgiving standards, Blink’s revenue is meager, totaling an estimated $5.5 million in 2020. ChargePoint Inc., which announced plans to go public via a special purpose acquisition company last year, generated $144.5 million in revenue in 2020, according to a January filing. EVgo Services LLC, which is nearing a similar deal to go public through a SPAC, has a smaller charging network than Blink but more than double the sales -- an estimated $14 million in 2020. Despite the wildly different revenue figures, all three companies have an enterprise value of between $2.1 billion and $2.4 billion.Blink warned in a May filing that its finances “raise substantial doubt about the Company’s ability to continue as a going concern within a year,” a required disclosure when a company doesn’t have enough cash on hand for 18 months of expenses.“Electric is real. The stock prices of companies in the space are not,” said Erik Gordon, an assistant professor at University of Michigan’s Ross School of Business. “The dot-com boom produced some real companies, but most of the overpriced dot-com companies were lousy investments. The electric boom will be the same story. Some great companies will be built, but most of the investors who chase insanely-priced companies will be crying.”Still, the recent market boom has breathed new life into Blink, allowing it to raise $232.1 million though a share offering in January. Roth Capital Partners as recently as Friday recommended buying the stock, giving it a price target of $67, 29% above the current level.Shares fell 2.3% to $52.10 in New York Monday.The company’s prospects rely on exponential EV growth, and Farkas in January discussed plans to deploy roughly 250,000 chargers “over the next several years” and often touts the company’s ability to generate recurring revenue from its network.Currently, the company says it has 6,944 charging stations in its network. An internal map of Blink’s public fleet lists about 3,700 stations available in the U.S. By contrast, ChargePoint boasts a global public and private charging network that’s more than 15 times larger.Unlike some of its competitors, Blink’s revenue model hinges in part on driving up utilization rates, which for now remain in the “low-single-digits,” too scant to generate significant revenue, Farkas said during a November earnings call. He told Bloomberg that use will increase as EVs become more popular.For most chargers in operation now, utilization probably must reach 10%-15% to break even, although profitability depends on many other factors such as a company’s business model, electricity rates and capital costs, according to BloombergNEF Senior Associate Ryan Fisher.Blink was an early market leader among charging companies but has lost its lead and now controls about 4% of the sector in Level 2 public charging, said Nick Nigro, founder of Atlas Public Policy, an electric car consulting and policy firm.Blink has also acknowledged “material weaknesses” over its financial reporting, disclosed in U.S. Securities and Exchange Commission filings dating back to 2011. The company says it has hired an accounting consultant to review its controls and is making necessary changes.Origin StoryBlink’s colorful origin story has been a prime target of short-sellers. It traces back to 2006 when it formed as shell company New Image Concepts Inc. to provide “top-drawer” personal consulting services related to grooming, wardrobe and entertainment, according to an SEC filing.In December 2009, the company entered a share exchange agreement with Car Charging Inc. Farkas joined the company as CEO in 2010, after working as a stockbroker and investing in companies including Skyway Communications Holding Corp., which the SEC deemed a “pump-and-dump scheme” during the years Farkas held shares. (Farkas said he was a passive investor, was unaware of any misdeeds and “had no involvement in any capacity in the activities of Skyway.”)In 2013, Farkas oversaw Car Charging’s $3.3 million purchase of bankrupt Ecotality, which had received more than $100 million in U.S. Department of Energy grants to install chargers nationwide. The company later changed its name to Blink.Since then, Blink has been plagued by executive turnover, with three of five board members departing between November 2018 and November 2019. The company has had two chief financial officers and three chief operating officers since 2017. One former COO, James Christodoulou, was fired in March 2020. He sued the company, accusing it of potential securities violations, and reached a settlement with Blink, which denied any wrongdoing, for $400,000 in October.Financier Justin Keener, a one-time major Blink shareholder whose capital assisted the company’s 2018 Nasdaq listing, and the company he operated were charged last year for failing to register as a securities dealer while allegedly selling billions of penny-stock shares unrelated to Blink. He said he has since divested from Blink and now owns “a relatively small number of common shares” as a result of a settlement of a warrant dispute with the company. Keener denies the SEC allegations.Farkas told Bloomberg he has cut all ties to Keener, was unaware of any investigations going on while they worked together and has no knowledge of any wrongdoing by Keener.The surging stock has brought a windfall to Farkas, Blink’s largest shareholder. On Jan. 12, after shares rallied to records, he sold $22 million of stock, according to Bloomberg data. Farkas’s total compensation, including stock awards, totaled $6.5 million from 2016 to 2019, equivalent to more than half the company’s revenue. Included in his 2018 compensation were $394,466 in commissions to Farkas Group Inc., a third-party entity he controlled that Blink hired to install chargers.Farkas said his compensation is justified given that he had personally invested in the company’s formation and had for many years received shares in lieu of salary.More recently, Blink board member Donald Engel followed the CEO’s lead.He sold more than $18 million of shares during the past two weeks.(Updates share price in 15th paragraph and market value in fourth.)For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2021 Bloomberg L.P.

  • 15 Undervalued Stocks With Strong Earnings Growth in 2021

    Many companies have weathered the pandemic well, but their stock prices don't always reflect their potential for higher earnings.

  • What Is A Dividend? Plus The 5 Best Dividend Stocks Now

    What is a dividend and which companies have the best-yielding dividends? Read on for a primer on how best to approach this method of investing.

  • Bitcoin At $100,000 Before The Year Is Out, Says Novogratz

    Former hedge fund manager Michael Novogratz said Monday that Bitcoin (BTC) could more than double to $100,000 by the end of 2021 as more people are allowed to make purchases using the cryptocurrency, Bloomberg reported. What Happened: “You’re going to see every company in America do the same thing,” said the founder of Galaxy Digital Holdings Ltd. (OTC: BRPHF), a cryptocurrency investor company in an interview on Bloomberg Television. “It doesn’t have to be a lot. It’s the messaging that matters, you’re seeing the herd here, and it’s coming.” Novogratz praised Tesla Inc (NASDAQ: TSLA) CEO Elon Musk and called him a “genius” pointing to his decision to “listen to the people.” “One of the things that connect Bitcoin, and Tesla and solar stocks and ESG investing is millennials and Gen Z, young people are buying into the future, and they see cryptocurrencies — Bitcoin and other cryptos — as their currencies,” said Novogratz. Why It Matters: On Monday, Tesla said it had invested an aggregate of $1.5 billion of cash in BTC. The automaker said it would start to accept the apex cryptocurrency as a payment option in the future on a limited basis. MicroStrategy Incorporated (NASDAQ: MSTR) CEO Michael Saylor, an ardent BTC supporter, called the cryptocurrency, the “scarcest asset in the world,” Bloomberg reported separately. MicroStrategy holds 71,079 bitcoins that it purchased at an aggregate purchase price of $1.145 billion at an average purchase price of nearly $16,109 per bitcoin, according to an SEC filing. See Also: MicroStrategy Just Can't Get Enough Of Bitcoin — To Now Raise 0M In Debt To Fund Purchase On Monday, multiple analysts and commentators expressed their thoughts on Tesla’s Bitcoin purchase in a largely positive manner. Price Action: BTC traded 20.51% higher at $46,250.54 at press time. Grayscale Bitcoin Trust (OTC: GBTC) closed 20.62% higher at $45.69 on Monday. Latest Ratings for GBTC DateFirmActionFromTo Feb 2018BuckinghamInitiates Coverage OnSell Jul 2015WedbushInitiates Coverage onOutperform View More Analyst Ratings for GBTC View the Latest Analyst Ratings See more from BenzingaClick here for options trades from BenzingaBitcoin May Have Shot Past ,000 But Tesla Euphoria Has Hit Smaller Altcoins Even HarderElon Musk Tweets Drove Crypto Community Mad But Mark Cuban Says Dogecoin 'Not A Bad Look'© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • Analysis: Lost in the 'Gamestonks' mania - What is GameStop actually worth?

    Shares of video game retailer GameStop Corp have been on a wild ride. The company's shares soared more than 1,600% in January as retail investors, urged on by popular Reddit forum WallStreetBets, bought the stock as a way to punish hedge funds that had taken an outsized short bet against it. While few on the forums have posted their breakdown of what they think is the fair value of a share of GameStock, a popular YouTube streamer named Keith Patrick Gill, who posted under the name the Roaring Kitty, suggested in videos prior to the short squeeze that it was worth at least $50 per share.

  • Wells Fargo: These 2 Stocks Could Climb at Least 30%

    After January’s sell-off, February’s first week of trading saw the stock market firmly back in bull mode. All 3 major indexes closed off the week at or at touching distance from all-time highs, as the market reacted favorably to the latest job data and the Democrats’ decision to move forward with a $1.9 trillion stimulus package. So, where is the market heading next? Investment firm Wells Fargo sees long-term appreciation ahead for the stock markets. Attempting to peer into the future, Wells Fargo’s senior global equity strategist Scott Wren says, “Playing into our expectation for a meaningful bounce back from the pandemic-induced contraction of last year are factors we have discussed in the past and we believe will continue to be the drivers this year. Positive vaccine news, easy money policies being pursued by the Federal Reserve, and additional anticipated government stimulus have all helped the stock market...” Against this backdrop, Wells Fargo analysts are pounding the table on two stocks, noting that each could surge at least 30% in the year ahead. After running the two through TipRanks’ database, we found out that the rest of the Street is also standing squarely in the bull camp. Guild Holdings (GHLD) The stock market may get more headlines, but real estate is where most Americans hold their wealth. The two markets intersect when real estate companies go public. Guild Holdings is a mortgage company, originating, selling, and servicing home loans in the US residential mortgage sector. The company has a footprint across most of the States, and operates through retail and word-of-mouth channels. The San Diego-based company held its IPO last year, in the latter half of October. The opening was only moderately successful, with the stock holding at or near $15, below the $17 planned. Guild Holdings sold 6.5 million shares, which was below the 8.5 million anticipated. The IPO raised $97.5 million, and the company boasts a current market cap ofreiterate our Overweight rating on GHLD. $972.6 million. Looking ahead, Wells Fargo analyst Donald Fandetti thinks the company is well-positioned to benefit in the current climate. "Despite rising interest rates, we believe management struck a confident posture that their business model should hold up relatively well given their purchase/retail orientation. There is also opportunity to fill in their branch footprint in areas such as the Northeast. The rising 10-year yield has shifted investor sentiment further negative for originators," the analyst opined. In this environment, Fandetti continues to "favor value and purchase mkt exposure," hence his bullish take on the stock. In line with these comments, Fandetti rates GHLD an Overweight (i.e. Buy), and his $22 price target indicates a potential for 36% upside growth in the year ahead. (To watch Fandetti’s track record, click here) Similarly, the rest of the Street is getting onboard. 4 Buys and 1 Hold assigned in the last three months add up to a Strong Buy analyst consensus. The stock is selling for $16.21, and its $19.30 average price target implies a 19% one-year upside. (See GHLD stock analysis on TipRanks) PDC Energy (PDCE) Next up, PDC Energy, is a hydrocarbon producer based in Denver, Colorado. The company has operations in the Wattenberg Field of its home state, as well as the Delaware Basin of the Texas Permian oil formation. PDC produces oil, natural gas, and natural gas liquids through an aggressive horizontal drilling program. PDC saw revenues slip in 1Q20, and slip farther in the second quarter – but the top-line moved in the right direction in Q3. The company brought in $303 million that quarter, and on an adjusted basis showed a profit of $1.04 per share. Looking ahead to the fourth quarter report, due out at the end of February, the company is expected to show 92 cents per share in earnings. In some additional positive metrics, PDC produced a total of 192,000 barrels of oil equivalent per day in the third quarter, for a total of 17.7 million Boe. The company generated net cash from operations of $280 million, and saw a free cash flow of $225 million. During Q3, PDC was able to pay down $215 million worth of debt. Analyst Thomas Hughes, in his note on the stock for Wells Fargo, is impressed by the company’s free cash flow and potential for future production. “FCF generation will drive absolute debt below $1.5bn by the end of 1Q21 per our model, an important figure as shareholder returns (buybacks first) are predicated on this achievement… As debt falls below $1.5bn, the company will likely take a formulaic approach to distributing FCF… While heightened CO regulatory risk exists, PDCE has been successful building a backlog of permits and DUCs for forward development,” Hughes wrote. To this end, Hughes rates the stock an Overweight (i.e. Buy), and his $33 price target shows his confidence in a 30% upside for the next 12 months. (To watch Hughes’ track record, click here) It’s not often that the analysts all agree on a stock, so when it does happen, take note. PDCE’s Strong Buy consensus rating is based on a unanimous 10 Buys. The stock’s $27.90 average price target suggests a 10% and a change from the current share price of $25.35. (See PDCE stock analysis on TipRanks) To find good ideas for stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights. Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.

  • Tesla buying $1.5 billion in bitcoin opens the company up to further scrutiny

    Tesla CEO Elon Musk just spent $1.5 billion of his company's cash on bitcoin. But did he also just make it tougher to invest in the company?

  • Dow Jones Futures: Stock Market Rally Overheating? Nvidia Hits New Buy Point, As Bitcoin Tops $47,000

    Dow Jones futures were little changed late Monday following record highs in the stock market rally. Bitcoin surged 18% on Tesla's Bitcoin news.

  • Green Tech Could Create The First Trillionaire

    The green tech boom is just getting started, but it’s already looking like it may just wind up crowning the world’s first trillionaire

  • Cannabis Countdown: Top 10 Marijuana And Psychedelic Stock News Stories Of The Week

    Welcome to the Cannabis Countdown, the Legal Marijuana Industry’s Number One Curated Weekly News Recap. In This Week’s Edition, We Recap and Countdown the Top 10 Cannabis and Psychedelic Stock News Stories for the Week of February 1st – 7th, 2021. Without further ado, let’s get started. * Yahoo Finance readers, please click here to view the full article. 10. 4 Cannabis Stocks That Could Benefit From the “Short Squeeze” Revolution Unless You’ve Been Living Under a Rock the Past Few Weeks, You’ve Certainly Heard About the Massive GameStop Short Squeeze That Was Triggered By the Large Reddit Investment Group WallStreetBets A group of Wall Street hedge funds holding large short positions in stocks like GameStop (NYSE: GME), AMC Entertainment (NYSE: AMC), and Blackberry (NYSE: BB) were completely blindsided by the power of a single Reddit group and in a scramble to cover their short positions, were forced to take staggering losses. With investors everywhere wondering where the next big squeeze play will come from, here are 4 Cannabis Stocks with all the right ingredients for a major GME style Short Squeeze. READ FULL CANNABIS SHORT SQUEEZE ARTICLE 9. Forget Cannabis: Psychedelic Stocks Could Be the Next Big Thing for the Decade Cannabis Stocks Made Enormous Wealth for its Shareholders in 2018 and 2019 After Pot Was Legalized in Canada and If You Happened to Missed That Rally, Psychedelic Stocks Could Be Next Up for a Major Breakout Regulatory support and encouraging research outcomes sent Psychedelic Stocks like MindMed (+860%) and Numinus Wellness (510%) through the roof in 2020. The first Psychedelics ETF, the Horizons Psychedelic Stock Index ETF (NEO: PSYK) is currently trading at $9.4 and the ETF’s top holdings include Compass Pathways (NASDAQ: CMPS), Johnson & Johnson (NYSE: JNJ), MindMed (NEO: MMED) (OTCQB: MMEDF) (FRA: MMQ), Numinus Wellness (TSXV: NUMI) (OTC: LKYSD) (FRA: LR23), Field Trip Health (CSE: FTRP) (OTC: FTRPF), Cybin Inc. (NEO: CYBN) (OTC: CLXPF), Mydecine Innovations (OTC: MYCOF) and Revive Therapeutics (OTCPK: RVVTF). READ FULL PSYCHEDELIC STOCKS ARTICLE 8. A Global Cannabis Pharmaceutical Leader and the Smart Money Heavyweight Betting on Them The Cannabis Pharma Market is Quickly Becoming an Enormous Opportunity and Investors Looking to Get Involved Should Follow the “Smart Money”, Which in the MJ Sector Means Paying Close Attention to What Canopy Growth Founder Bruce Linton is Up to GW Pharmaceuticals (NASDAQ: GWPH) is leading the charge in the burgeoning cannabis pharma space. Following recent news that Jazz Pharmaceuticals (NASDAQ: JAZZ) will acquire GW Pharma for $7.2 billion, GWPH shares are now trading at a whopping $214.57 per share. The tremendous performance of GW Pharma has investors searching for the Cannabis pharma sector’s next big winner and one such company with all the right ingredients to potentially experience a similar rise is Creso Pharma (OTC: COPHF). Fresh off leading Canopy Growth (NASDAQ: CGC) shareholders to all-time gains of +4,160%, Bruce Linton’s sights are set on the cannabis pharma space joining forces with sector leader Creso Pharma, which has global operations in lucrative markets worldwide. READ FULL CANNABIS PHARMA ARTICLE 7. Champignon Brands CEO Dr. McIntyre Publishes Article on New Rapid Mood Screener for Manic Symptoms and Bipolar I Disorder Features to Address Unmet Clinical Need Depressive Episodes and Symptoms of Bipolar I Disorder Are Commonly Misdiagnosed as Major Depressive Disorder (MDD) in Primary Care Champignon Brands (OTCQB: SHRMF) announced the publication of an article led by the company’s CEO Dr. Roger McIntyre on the novel and pragmatic Rapid Mood Screener (RMS), which was developed to screen for manic symptoms and bipolar I disorder features in order to help address this unmet clinical need. The article titled: “The Rapid Mood Screener (RMS): a Novel and Pragmatic Screener for Bipolar I Disorder” is published on the website Taylor & Francis Online. READ FULL CHAMPIGNON BRANDS ARTICLE 6. Red White & Bloom Completes USD $6.12 million Non-Convertible Debenture Financing The Non-Convertible Debenture is Unsecured and Bears Interest at a Rate of 7%, With the Principal Amount and Accrued Interest Payable on April 1, 2022 Red White & Bloom (OTCQX: RWBYF) announced that it closed a debenture unit financing to an arm’s-length investor on a private placement basis. RWB intends to utilize the proceeds from the financing for the expansion of its Platinum Vape business as it prepares to launch in Arizona, to fund certain pre-closing operational plans for its previously announced Illinois THC Cultivation Center License acquisition and for general corporate and working capital. READ FULL RWB ARTICLE 5. Curaleaf Opened its 34th Dispensary in Florida, Inching Closer to 100 Retail Stores in the U.S. Curaleaf’s New Store, Located at 5935 4th Street, is Also the Company’s 34th Dispensary in the State, and 98th in the United States Curaleaf (OTCQX: CURLF) opened the second dispensary in St. Petersburg, Florida. Curaleaf St. Petersburg North brings a diversified portfolio of Cannabis products, including America’s number 1 oil brand, Select, but also some novel products, like quick-acting Nano Chews and Nano Drops, and Sublingual Tablets, among others. READ FULL CURALEAF ARTICLE 4. MindMed Streamlines Leadership with Further Emphasis on Integrating Psychedelic Drug Development with Digital Medicines and Therapeutics J.R. Rahn to Become MindMed’s Sole CEO; Perry Dellelce to Become Company Chair and Stephen Hurst Retires as Executive But Remains on MindMed Board MindMed (OTCQB: MMEDF), a Psychedelic medicine biotech company, streamlined its leadership team to further develop the company’s strategy of integrating its psychedelic clinical development programs with innovative digital technologies. Under the MindMed 2.0 leadership team, the company is also actively growing its digital medicine division for psychedelic medicines through the hiring of new technologists and undertaking potential technology platform acquisitions. READ FULL MINDMED ARTICLE 3. Creso Pharma Applauds Start of Over-the-Counter CBD Product Sales in Australia With Low-Dose CBD Products Now Eligible to Be Sold By Australian Pharmacies OTC Without a Prescription, Creso Pharma is Well-Positioned to Capitalize on This Major New Market Opportunity Estimated to Be Worth Over $200 Million Creso Pharma (OTC: COPHF) announced the company welcomes the commencement of over-the-counter (OTC) sales of low-dose cannabidiol (CBD) products in Australian pharmacies, which officially began on February 1, 2021. “Today is a major milestone for the Australian medicinal cannabis industry, which we anticipate will grow rapidly over the coming months. The TGA’s decision to allow the sale of low–dose CBD products to consumers without a prescription provides Creso Pharma with another exciting opportunity to grow in Australia and another potential revenue stream for the Company,” said Creso’s Adam Blumenthal. READ FULL CRESO PHARMA ARTICLE 2. More Psychedelic Companies Are Going Public in 2021 The Nascent Psychedelic Industry is Booming as Several Companies Have Gone Public and More are Expected to Follow This Route in 2021 to Attract More Capital From Institutional and Retail Investors Competition among the dozens of biopharmaceutical companies is fierce. Many are seeking more capital to conduct expensive and lengthy drug trials and develop intellectual property to synthesize the molecules to help treat various mental disorders. The companies that can bring their Psychedelic drugs to the market first will emerge from the pack and could likely hit a home run. “Within the next six to 12 months, we will see an arms race in the psychedelic space as companies try to innovate and get their drugs to trials and to the market,” says Jason Spatafora, co-founder of MarijuanaStocks.com and head trader at TrueTradingGroup.com. ATAI Life Sciences, a Berlin-based biotech company that is researching both Psychedelic and nonpsychedelic compounds, is expected to go public in 2021. READ FULL PSYCHEDELIC IPOS ARTICLE 1. Jazz Pharmaceuticals to Acquire GW Pharmaceuticals plc, Creating an Innovative, High-Growth, Global Biopharma Leader Enhanced Product Diversification of the Combined Company is Expected to Provide Accelerated Double-Digit Revenue Growth Jazz Pharmaceuticals (NASDAQ: JAZZ) announced it has entered into a definitive agreement to acquire GW Pharmaceuticals (NASDAQ: GWPH) (OTC: GWPRF) for $220.00 per American Depositary Share (ADS), in the form of $200.00 in cash and $20.00 in Jazz ordinary shares, for a total consideration of $7.2 billion, or $6.7 billion net of GW cash. The transaction, which has been unanimously approved by the Boards of Directors of both companies, is expected to close in the second quarter of 2021. READ FULL GW PHARMA ARTICLE Photo by Esteban Lopez on Unsplash See more from BenzingaClick here for options trades from BenzingaCannabis Countdown: Top 10 Marijuana And Psychedelics Industry News Stories Of The WeekCannabis Countdown: Top 10 Marijuana And Psychedelic Stock News Stories Of The Week© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.